Risk is an inevitable aspect of medical care with recent studies illustrating the potential harm that can be done to patients using diclofenac with a cardiac history and codeine in paediatric patients. These studies apply in both cases to small subsets of each population however the implications have led health care bodies into disarray with the result that a large number of patients are no longer able to avail of these useful painkillers due to nationwide bans resulting in longer hospital stays and patients discharged on control drugs.
The background to the change in regulation of these two drugs is highlighted by The Medicines and Healthcare Products Regulatory Agency (MHRA) who have stated that diclofenac should not be used by people with underlying heart conditions or hypertension due to an increased risk of myocardial infarction and stroke 1 . The use of codeine in children and adolescents has also been restricted after a European safety review was triggered by case reports of children who received codeine after tonsillectomy for obstructive sleep apnoea (OSA) and developed rare, but life-threatening adverse events 2 .
A report, published in 2012, documented the cases of three children who died after receiving treatment with codeine after tonsillectomy 3 . Although the number of documented cases of codeine-related deaths remains small, the complications and legal outcomes of tonsillectomy malpractice claims found that the incidence of codeine-related deaths was much higher than expected. Using data from the Lexis Nexis Mega Jury Verdicts and Settlements database from 1984-2010 it was found that 18 percent of death claims and 5 percent of injury claims resulted from the use of opioids rather than haemorrhage which would be expected 4 .
Both medications are routinely used post operatively following a wide range of procedures in many specialities. While many of these patients are often well those with IHD other cardiovascular illnesses are encountered. Given the prevalence of children with OSA being less than 0.7% and those with CYP2D6 enzyme abnormalities (linked to abnormal codeine metabolism) being even less these patients are rarely encountered 5 .
Our patients' interest are first and foremost and providing them with adequate pain relief following surgical procedures is vitally important. Unfortunately we have blanketing guidelines which fail to take into account the low risk to most patients and certainly fail to take into account both medical expertise and patient choice and sensibility. Antiphospholipid antibody syndrome (APS) is traditionally characterized by the presence of circulating antiphospholipid antibodies (aPL) that lead to an increased risk of thrombosis and pregnancy morbidity. 1,2 Considered rare, diffuse alveolar hemorrhage (DAH) is thought to be a non-thrombotic manifestation of APS, likely secondary to aPL induced pulmonary capillaritis. 3 The diagnosis needs to be considered even in the absence of known thrombosis, as multiple recent case reports have identified DAH as the presenting symptom.
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A 35-year-old mother of four from El Salvador presented with a two day history of pronounced dyspnea and hemoptysis. Two years prior she had been diagnosed with adult-onset
